Canadian Influenza Vaccines market size stood at USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.

Influenza, also known as the flu, is an infection of the upper airway caused primarily by the influenza A and B viruses. Symptoms can include fever, cough, muscle aches and pains, headache, sore throat, etc. It is ranked among the top 10 leading causes of death in Canada. Each year, it is estimated that influenza causes on average 12,200 hospitalizations and 3,500 deaths in Canada. Influenza viruses circulate in Canada year-round. Two influenza vaccine types are widely available in the market. These are inactivated influenza vaccine (IIV) and live attenuated influenza vaccines (LAIV). The influenza vaccine markethas increased tremendously over the past few years. Several factors influence the raised market value, including the increase of the awareness of the disease among the people, funding, and the fear of the influenza pandemic.



Market Drivers

The increasing prevalence of Influenza-induced diseases among infants, increasing awareness regarding vaccines among patients are accelerating the growth of this market. The Canadian national influenza vaccination coverage goals for seniors aged 65 and older and adults aged 1864 years with certain chronic medical conditions (CMC) were set at 80% in 2019 to be reached by 2028. The rise in the population of immunity-compromised individuals can act as a catalyst for market growth. An increase in the development and manufacturing of vaccines would enhance the market growth. The increasing intergenic variability among various influenza virus strains has led to increasing demand for developing influenza vaccines compatible with all influenza viruses.